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Background: Despite the availability of patented non-invasive methods, evaluation of the degrees of liver fibrosis
remains difficult when conducting a retrospective study. Such inadequacy is largely caused by requirement of
biochemical parameters rarely performed in routine clinical tests. We developed a novel fibrosis HB-F score using
commonly performed tests for HBV infected patients.
Methods: 424 patients with chronic HBV infection were included. Using clinical and virological data, HB-F score was
developed from a training cohort (n = 213) and validated in a separate cohort (n = 211). The performance was
compared with five other unpatented scores using ROC curves.
Results: Univariate and multivariate analysis revealed that age, AST/ALT ratio, platelet count and prothrombin time
prolongation were significantly associated with the ISHAK fibrosis score, and were used to calculate the HB-F score.
When HB-F was used to assess prominent fibrosis and cirrhosis, the AUC was 0.81 and 0.80 respectively in the
training cohort, and 0.80 and 0.76 respectively in the validation cohort. HB-F had the highest AUC compared with
other scores. Furthermore, in assessing paired liver biopsies with increase or decrease of ISHAK scores, HB-F showed
significant change in the same direction.
Conclusions: A new non-invasive score was developed, which could be used to assess severity of liver fibrosis in
retrospective longitudinal studies in HBV patients.
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It has been estimated that 350 millions patients are
infected by hepatitis B virus (HBV) worldwide [1].
Chronic HBV infection may lead to severe sequelae
such as liver fibrosis and cirrhosis [1]. Liver fibrosis is a
progressive damage which not only impairs liver func-
tions but also increases the risk of hepatocellular carcin-
oma [2]. The progression of fibrosis has multiple stages
which are commonly defined by ISHAK or METAVIR
scoring systems [3-5]. An advanced fibrosis score repre-
sents a serious clinical condition which requires careful
medical managements. To prevent disease progression,
we need to detect liver fibrosis at an earlier stage and to* Correspondence: chautingy@gmail.com
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reproduction in any medium, provided the orprovide adequate antiviral agent treatment [6]. In the
past decades, liver biopsy has been a gold standard for
the assessment of fibrosis stages. However, there are
several limitations when applying this method, such as
sampling bias, low platelet counts, prolonged prothrom-
bin time, massive ascites, patient’s intention and com-
pliance as well as scoring variations from different
pathologists [7]. Thus, other methods to accurately
assess liver fibrosis are continuously sought, especially
for non-invasive tests.
Ultrasound is one possible alternative for non-invasive
assessment. FibroScan and Acoustic radiation force im-
pulse (ARFI) elastography have been used for evaluation
of fibrosis in chronic hepatitis B or C patients. However, it
was found that the accuracy of FibroScan and ARFI was
greatly interfered by higher degrees of necroinflammation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Basic clinicopathological data for hepatitis B
patients included
Characteristics Training cohort Verification
(n = 213) cohort (n = 211)
Age at biopsy in years,
mean ± SD
44.4 ± 11.8 45.6 ± 11.4




Periportal inflammation 1.0 ± 0.8 0.9 ± 0.8
Confluence necrosis 0.3 ± 1.0 0.2 ± 0.8
Focal inflammation 1.9 ± 0.7 2.0 ± 0.7
Portal inflammation 2.2 ± 1.0 2.2 ± 0.9
ISHAK fibrosis score, n (%)
0 1 (1) 1 (1)
1 28 (13) 28 (13)
2 32 (15) 32 (15)
3 70 (33) 71 (34)
4 21 (10) 21 (10)
5 46 (22) 45 (21)
6 15 (7) 13 (6)
HBeAg-positive, n (%) 109 (51) 91 (43)
Biochemistry, mean ± SD
AST (IU/mL) 91.3 ± 83.6 94.9 ± 100.1
ALT (IU/mL) 170.1 ± 173.8 166.2 ± 177.9
AST/ALT 0.6 ± 0.3 0.6 ± 0.3
AFP (ng/mL) 10.5 ± 22.2 20.4 ± 82.0
Bilirubin (mg/dL) 1.0 ± 0.7 1.0 ± 0.4
GGT (IU/L) 69.0 ± 77.0 60.1 ± 57.3
Albumin (g/dL) 4.6 ± 0.3 4.5 ± 0.4
Platelet (×103/mm3) 188.2 ± 54.2 189.2 ± 49.4
Prothrombin time
prolongation (sec)
1.0 ± 0.6 1.0 ± 0.8
White blood cell (×103/mm3) 5.7 ± 1.7 5.5 ± 1.6
Hemoglobin (g/dL) 15.1 ± 1.4 15.2 ± 1.3
Alpha-1 globulin (g/dL) 0.2 ± 0.1 0.2 ± 0.0
Alpha-2 globulin (g/dL) 0.8 ± 0.2 0.8 ± 0.1
Beta globulin (g/dL) 0.8 ± 0.1 0.7 ± 0.1
Gamma globulin (g/dL) 1.5 ± 0.4 1.4 ± 0.4
Albumin/Globulin 1.5 ± 0.3 1.5 ± 0.3
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cially in chronic hepatitis B patients [8-11].
Recently, a number of fibrosis scores have been pro-
posed as surrogates to liver biopsy. These scores are often
composed of a combination of biochemistry measure-
ments and clinical parameters. For example, the AAR
score is based on the ratio of aspartate transaminase
(AST) and alanine transaminase (ALT) values [12]. The
APRI score is the AST value divided by platelet counts
[13]. The early AAR and APRI scores motivate several
subsequent scores where the ratios of AST/ALT or AST/
platelet counts are employed as part of their equations.
The Fibrosis index (FI) score is composed of platelet
counts and serum albumin [14]. The Fibroindex consists
of AST, platelets, and gamma globulin measurements
[15]. The FIB-4 index includes age, AST, ALT and platelet
counts [16,17]. A patented test, named FibroTest, is
composed of alpha2-macroglobulin, haptoglobin, gamma
glutamyl transpeptidase (GGT), age, bilirubin, apoA1, and
sex. Most of these markers were initially derived from
patients with chronic hepatitis C but were subsequently
tested in chronic hepatitis B patients. Meta-analysis for
the performance of biomarkers in HBV or hepatitis C
virus (HCV) infection showed that assessment of the
treatment efficacy on fibrosis progression was equally
effective when estimated by either FibroTest or biopsy.
Despite the great performance of FibroTest, there were
still no sufficient data to show that biomarker or biopsy
alone could make accurate fibrosis staging in patients with
chronic HBV infection [18]. Furthermore, the requirement
of measuring several uncommon tests to calculate the
score greatly limited its use in retrospective study [19-21].
We were thus motivated to formulate a new hepatitis
B-fibrosis score (HB-F) using commonly performed




Under approval of Institutional Review Board, Chang
Gung Medical Council, this study was conducted at
Liver Research Center, Chang Gung Memorial Hospital,
Taiwan. A total of 424 adult patients with compensated
chronic hepatitis B were recruited (Table 1). All of them
have signed informed consent forms. They received liver
biopsy between January 2007 and July 2009. No antiviral
agents were given to these patients before biopsy was
taken and patients with other viral co-infections, such as
HIV, hepatitis C or hepatitis D co-infections were pre-
excluded. Hepatitis B e Antigen (HBeAg) and antibodies
to HBeAg (anti-HBe) were measured before liver biopsy.
Biochemistry were assessed at the same time of liver
biopsy, including AST, ALT, bilirubin, gamma glutamyl
transpeptidase (GGT), albumin, alpha-1 globulin, alpha-2 globulin, beta globulin, gamma globulin and albumin/
globulin ratio. Hematology tests were also performed
at same time point, including hemoglobin, platelet
count, white blood cell, prothrombin time, and alpha-
fetoprotein (AFP).
Histologic evaluation of biopsy samples were carried
out at the Pathology Department, according to ISHAK’s
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(no fibrosis), FS1 (fibrous expansion of some portal
areas), FS2 (fibrous expansion of most portal areas), FS3
(fibrous expansion of most portal areas with occasional
portal to portal bridging), FS4 (fibrous expansion of
most portal areas with marked bridging), FS5 (marked
bridging with occasional nodules, incomplete cirrhosis),
and FS6 (cirrhosis).
After biopsy, subjects of each ISHAK stage were
randomly assigned into two cohorts: the training cohort
(n = 213) and the validation cohort (n = 211), for formula-
deriving and validation purposes respectively. This way,
subjects were evenly split across all ISHAK stages. Clinical
parameters and biochemistry measurements were indi-
vidually tested for their association to the ISHAK fibrosis
stages. The associated factors were then combined to pro-
duce the HB-F score. The score was then validated using
the validation cohort, and its performance was compared
with five other reported scores (AAR, FIB-4, FI, APRI,
Fibroindex), which were all originally derived from hepa-
titis C infected patients.
Statistical analysis
Clinicopathological data distribution was compared be-
tween the training and validation cohorts by either
Chi-square tests or two-sample t-tests with unequal vari-
ance. Linear regression was used for the univariate and
multivariate analysis to assess the association between theTable 2 Univariate and multivariate analysis for factors assoc
Characteristics Beta (95% CI)
Age at biopsy 0.035 (0.018, 0.052)
Male 0.046 (−0.597, 0.506)
HBeAg-positive −0.496 (−0.943, -0.048)
AST (IU/mL) 0.001 (−0.001, 0.004)
ALT (IU/mL) 0.000 (−0.001, 0.001)
AST/ALT 1.881 (1.199, 2.563)
AFP (ng/mL) 0.012 (0.001, 0.023)
Bilirubin (mg/dL) 0.142 (−0.168, 0.452)
GGT (IU/L) 0.006 (0.002, 0.009)
Albumin (g/dL) −1.440 (−2.839, -0.042)
Platelet (×103/mm3) −0.012 (−0.015, -0.009)
Prothrombin time prolongation (sec) 0.781 (0.404, 1.157)
White blood cell (×103/mm3) 0.049 (−0.093, 0.192)
Hemoglobin (g/dL) 0.053 (−0.125, 0.231)
Alpha-1 globulin (g/dL) −0.898 (−2.683, 0.886)
Alpha-2 globulin (g/dL) −0.505 (−1.746, 0.736)
Beta globulin (g/dL) −0.808 (−2.160, 0.545)
Gamma globulin (g/dL) 0.214 (−0.327, 0.754)
Albumin/Globulin −0.422 (−1.180, 0.335)clinical/ laboratory parameters and ISHAK fibrosis scores.
Significance levels of correlation were assessed by Wald
test statistics. All the P-values were two-tailed. The Re-
ceiver Operating Characteristic (ROC) Curve was used to
examine the trade-off of sensitivity and specificity. The
performance of classification was assessed by the Area
Under Curve (AUC). The HB-F and FIB-4 scores of the
two biopsy examinations were assessed by paired t-tests.
Results
The distributions of subjects’ clinicopathological values
were presented in Table 1. The two cohorts had similar
number of subjects across all ISHAK stages without sig-
nificant disparity (P = 1.000). Additionally, comparison of
the age, gender, inflammation scores and the biochemistry
and hemogram values revealed no significant difference.
Univariate and multivariate associations of various
factors to ISHAK fibrosis stages were performed in the
training cohort (Table 2). Significant associations were
found in eight parameters, including age at biopsy,
HBeAg, AST/ALT ratio, AFP, GGT, Albumin, platelet and
prothrombin time prolongation (P < 0.05). Among them,
four parameters (age at biopsy, AST/ALT ratio, platelet
and prothrombin time prolongation) showed stronger as-
sociation (P < 0.001). A multivariate analysis of the four
parameters showed that all of them remained significant
(P < 0.05), indicating their independent association to the
ISHAK fibrosis stages.iated with liver fibrosis
P Adjusted beta (95% CI) P










< 0.001 −0.009 (−0.013, -0.005) < 0.001
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generate the HB-F score using the multiple regression
coefficients (Adjusted Beta) in Table 2, omitting the con-
stant term. The formula of HB-F score was written as:
HB-F = 0.018 × [Age] + 1.085 × [AST/ALT] - 0.009 ×
[Platelet (×103/mm3)] + 0.449 × [Prothrombin time pro-
longation (sec)]
In the training cohort, subjects with a more severe
fibrosis stage also had a higher range of HB-F score
(Figure 1). The score was then used to classify patients
with (FS > =5) or without cirrhosis (FS <5) and patients
with (FS > =4) or without severe fibrosis (FS < 4). The
AUCs were 0.810 and 0.799 for the distinction of severe
fibrosis and cirrhosis, respectively, in the training cohort.
Consistently, the corresponding AUCs were 0.797 and
0.757 respectively in the verification cohort. Both AUCs
were larger than 0.75 suggesting adequate capability of
HB-F in identifying severe fibrosis subjects (Figure 1).Figure 1 Performance of the HB-F fibrosis score in the training cohor
ISHAK fibrosis score (FS1-FS6). Gray boxes represented the 25%-75% quartil
ranges of HB-F scores in subjects stratified by FS < 5 (non-cirrhotic patients
subjects grouped by FS < 4 and FS > =4 (prominent fibrosis) (P < 0.001). (D)
patients (AUC = 0.799). (E) The ROC curve for the diagnosis of prominent fiWhen compared with five other reported methods,
HB-F had the highest AUC (Table 3, Figure 2). The next
three best scoring methods were FIB-4, Fibroindex and
APRI, respectively, but all had no statistically significant
difference when compared with HB-F score. AAR, on
the other hand, had a significantly inferior performance
in classifying both the cirrhosis and prominent fibrosis.
FI had an inferior performance in identifying prominent
fibrosis. The ROCs of all the methods were presented in
Figure 2.
A total of 33 subjects had received a second biopsy and
biochemistry examinations. They offered additional dis-
ease progression and remission data for evaluating the
change of HB-F and FIB-4 score under an increase or
decrease of ISHAK levels (Figure 3). FIB-4 was chosen
because it had the highest AUC among the benchmark
scores. The HB-F scores showed significant changes in the
same direction of an increment (P = 0.011) and decrement
(P = 0.015) of ISHAK levels. In contrast, FIB-4 did not
show such a correlated change.t of patients. (A) The ranges of HB-F scores in patients with different
es; The middle horizontal lines represented the median scores. (B) The
) and FS > =5 (cirrhosis) (P < 0.001). (C) The ranges of HB-F scores in
The ROC curve of the HB-F score for the diagnosis of cirrhosis
brosis patients (AUC = 0.810).
Table 3 Performance of six fibrosis score for evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B
Non-invasive index AUC (95% CI) Difference between areas (95% CI)* P*
Prominent fibrosis
HB-F (training) 0.810 (0.751, 0.861)
HB-F (verification) 0.797 (0.737, 0.849)
FIB-4 0.772 (0.709, 0.826) 0.0255 (−0.0236, 0.0746) 0.3087
Fibroindex 0.767 (0.704, 0.822) 0.0301 (−0.0298, 0.0899) 0.3251
ARPI 0.753 (0.689, 0.810) 0.0439 (−0.0302, 0.1180) 0.2454
AAR 0.630 (0.561, 0.696) 0.1670 (0.0947, 0.2390) < 0.0001
FI 0.724 (0.659, 0.784) 0.0728 (0.0093, 0.1360) 0.0246
Cirrhosis
HB-F (training) 0.799 (0.739, 0.851)
HB-F (verification) 0.757 (0.694, 0813)
FIB-4 0.727 (0.662, 0.786) 0.0297 (−0.0223, 0.0818) 0.2624
Fibroindex 0.722 (0.656, 0.781) 0.0351 (−0.0320, 0.1020) 0.3054
ARPI 0.698 (0.631, 0.759) 0.0589 (−0.0244, 0.1400) 0.1556
AAR 0.636 (0.568, 0.701) 0.1210 (0.0470, 0.1950) 0.0013
FI 0.717 (0.651, 0.777) 0.0403 (−0.0283, 0.1090) 0.2497
*Comparison between the AUC of HB-F (verification cohort) and those of the other scoring methods.
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In this study, a novel fibrosis score named HB-F was
formulated, by combination of four factors which was
highly significant in the association with ISHAK fibrosis
stages (P < 0.001). The HB-F score was developed from a
large cohort of HBV-infected patients, as HBV infection
is a major etiology of fibrosis in Taiwan. Although the
study also included other HBV-related factors such as
the presence or absence of HBeAg, this factor only
manifested marginal association to the ISHAK stages
(P = 0.03). Hence, the HBV-related factors were not in-
cluded in HB-F.
The four factors in HB-F score included age, the AST/
ALT ratio from biochemistry test, platelet count and
prothrombin time prolongation from hematological test.
The prothrombin time prolongation was the only factor
not previously included in other scores. Our multivariteFigure 2 The ROC curves of HB-F score and 5 other methods (AAR, FI
fibrosis (left) or cirrhosis (right) in the validation cohort.analysis suggested that it was an independently asso-
ciated factor to liver fibrosis. One limitation of this study
is that the performance is only assessed in HBV-related
patients. This is due to the high prevalence of HBV
infection in Taiwan and thus a need to develop reliable
fibrosis score for retrospective studies. Nevertheless, the
four factors in the equation are not HBV-specific. There-
fore, this score may be used to evaluate the fibrosis of
other etiologies such as HCV infection and alcohol, once
the corresponding validation is completed in these
subjects.
The proposed HB-F score was constructed by multiple
regression coefficients (Adjusted Beta). It is a challenge
for both pathologists and fibrosis scores alike to discern
the stage of early fibrosis (FS1 to FS3). This is also a
limitation of HB-F. However, Figure 1A showed the dis-
tribution of HB-F score increased as the ISHAK-stageB-4, FI, APRI, and Fibroindex) for the diagnosis of prominent
Figure 3 Comparison of HB-F and FIB-4 scores in determination of improvement or deterioration of liver fibrosis in paired biopsies.
Left, The second biopsy showed an increase of ISHAK fibrosis level (n = 12). Middle, The second biopsy showed an decrease of ISHAK fibrosis level
(n = 8). Right, The second biopsy showed the same ISHAK fibrosis level (n = 13).
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that HB-F might potentially be used for classifying the
very earlier stage fibrosis. A larger number of patients in
these two stages are needed for verification.
The HB-F score had superior performance than five
other HCV-derived scores in identifying both the prom-
inent fibrosis and cirrhosis patients, when assessed by
AUCs. However, FIB-4, Fibroindex and APRI all showed
very similar performance as in Figure 2 and Table 3,
particularly FIB-4 seemed to be almost equally effective.
However, when the scores were evaluated using paired
liver biopsies, HB-F proved to be a better score for
judgment of histology improvement or deterioration.
Additionally, a similar performance between HB-F and
other previous scores (FIB-4, FI, Fibroindex) suggested
that we could use these scores interchangeably for esti-
mation of fibrosis severity in retrospective studies whereseveral clinical parameters were missing for one of these
scores. In other words, our studies and the novel score
provided flexibility for retrospective studies where fibro-
sis evaluation was often limited by data availability.
Conclusions
In conclusion, we have formulated a new fibrosis score,
the HB-F, for chronic hepatitis B patients, by use of a
linear combination of age, AST/ALT ratio, platelet count
and prothrombin time prolongation values. Judging from
the AUC comparison, HB-F score is better than other
existing unpatented scores derived from hepatitis C patients.
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